Tevogen Bio highlights commitment to shareholder equity and innovative financing strategies while focusing on immunotherapy development.
Quiver AI Summary
Tevogen Bio, a clinical-stage immunotherapy biotech company led by CEO Ryan Saadi, is reaffirming its commitment to shareholder equity amid discussions on financing strategies in the industry. Dr. Saadi advocates for a model focused on operational efficiency, asset ownership, and self-sustaining financing without relying heavily on equity financing. Tevogen believes its assets are significantly undervalued due to accounting limitations, with a market cap per employee well above industry averages. The company is dedicated to developing affordable, advanced immunotherapies leveraging its wholly-owned intellectual property and plans to expand its artificial intelligence efforts. Tevogen aims to revolutionize patient access to personalized therapeutics while navigating the complexities of the biotech landscape.
Potential Positives
- Tevogen Bio emphasizes its strong asset base, suggesting a high intrinsic value not currently reflected on its balance sheet.
- The company boasts an operational efficiency metric indicating its market cap per employee is approximately 600% higher than the industry average.
- Tevogen Bio has a self-sustaining financing strategy, enabling it to explore funding avenues without diluting equity.
- The press release highlights positive safety data from a proof-of-concept clinical trial, signaling progress in its immunotherapy development efforts.
Potential Negatives
- The company acknowledges potential difficulties in securing additional capital to execute its business plan, signaling possible financial vulnerabilities.
- There is uncertainty about the impact of the recent business combination with Semper Paratus Acquisition Corporation on business relationships and operating results.
- The press release conveys a reliance on various factors for future growth, introducing significant risks related to execution, technological advancements, and market competition.
FAQ
What is Tevogen Bio's primary focus?
Tevogen Bio focuses on developing advanced immunotherapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases and cancers.
How does Tevogen Bio preserve shareholder equity?
Tevogen Bio prioritizes operational efficiency and a self-sustaining financing strategy, minimizing reliance on equity financing.
What makes Tevogen Bio's business model unique?
Tevogen Bio challenges traditional biotech financing norms to ensure long-term sustainability and accessibility in healthcare.
What intellectual property does Tevogen Bio own?
Tevogen Bio owns three granted patents and has numerous pending patents related to its innovative therapeutics and artificial intelligence.
How can employees gain shares in Tevogen Bio?
Every employee at Tevogen Bio automatically becomes a shareholder, aligning their interests with the company's long-term success.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TVGN Insider Trading Activity
$TVGN insiders have traded $TVGN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TVGN stock by insiders over the last 6 months:
- NEAL FLOMENBERG (See Remarks) sold 1,078,600 shares for an estimated $1,747,332
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TVGN Hedge Fund Activity
We have seen 28 institutional investors add shares of $TVGN stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PORTLAND GLOBAL ADVISORS LLC removed 1,854,517 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,910,152
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 408,228 shares (-20.6%) from their portfolio in Q3 2024, for an estimated $150,391
- BLACKROCK, INC. added 370,936 shares (+160.6%) to their portfolio in Q4 2024, for an estimated $382,064
- HGC INVESTMENT MANAGEMENT INC. removed 223,077 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $229,769
- NEW YORK STATE COMMON RETIREMENT FUND removed 119,500 shares (-94.5%) from their portfolio in Q4 2024, for an estimated $123,085
- GEODE CAPITAL MANAGEMENT, LLC added 107,566 shares (+31.2%) to their portfolio in Q4 2024, for an estimated $110,792
- FMR LLC added 103,513 shares (+1070.0%) to their portfolio in Q4 2024, for an estimated $106,618
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of
Tevogen Bio
(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:
TVGN
), a clinical-stage specialty immunotherapy biotech company, reaffirms his commitment to preserving equity for shareholders. Amid ongoing discussions about financing approaches in the biotech sector, Dr. Saadi emphasizes his distinct strategy, which prioritizes efficiency, asset ownership, and a path to revenue.
“I’m not opposed to the concept of equity financing, I believe that preserving equity is fundamental to preserving a Founder’s vision,” said Ryan Saadi, Founder and CEO of Tevogen Bio. “From a practical standpoint, it’s simply not relevant to us when you consider the following:
Strong Asset Base:
Tevogen Bio believes its assets are valued in the billions. This value is not reflected on Tevogen’s balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP.
Operational Efficiency:
Tevogen Bio’s market cap per employee is approximately 600% higher than the industry according to
Mr. Damodaran at the Stern School of Business at NYU
.
Self-Sustaining Financing Strategy:
While Tevogen may secure funds between now and when it starts generating revenue, it has multiple avenues to do so without selling equity.
Regarding the company:
Tevogen’s true value will become more widely recognized as awareness grows.
The best way to gain TVGN shares is through employment, as every employee is also a shareholder.
Tevogen’s business model challenges traditional biotech financing norms to ensure long-term sustainability.
The company remains committed to making advanced immunotherapies accessible and affordable.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen’s plans to expand its efforts in artificial intelligence; Tevogen’s ability to develop additional product candidates; Tevogen’s use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
